Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Mirtazapine
Published online by Cambridge University Press: 20 February 2025
Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Summary
Mirtazapine (2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine) is an atypical antidepressant with a molecular weight of 265.35 and an empirical formula of C17H19N3.
- Type
- Chapter
- Information
- The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 282 - 292Publisher: Cambridge University PressPrint publication year: 2025
References
Suggested Reading
Agüera-Ortiz, L, García-Ramos, R, Grandas Pérez, FJ, López-Álvarez, J, Montes Rodríguez, JM, Olazarán Rodríguez, FJ, Olivera Pueyo, J, Pelegrín Valero, C, Porta-Etessam, J. Focus on depression in Parkinson’s disease: a Delphi consensus of experts in psychiatry, neurology, and geriatrics. Parkinsons Dis 2021; 2021: 6621991.Google ScholarPubMed
Gordon, PH, Pullman, SL, Louis, ED, Frucht, SJ, Fahn, S. Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord 2002; 9(2): 125–126.CrossRefGoogle Scholar
Meco, G, Fabrizio, E, Di Rezze, S, Alessandri, A, Pratesi, L. Mirtazapine in l-dopa-induced dyskinesias. Clin Neuropharmacol 2003; 26(4): 179–181.CrossRefGoogle ScholarPubMed
Sid-Otmane, L, Huot, P, Panisset, M. Effect of antidepressants on psychotic symptoms in Parkinson disease: a review of case reports and case series. Clin Neuropharmacol 2020; 43(3): 61–65.CrossRefGoogle Scholar
References
AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 4 December 2022 via www.medicinescomplete.com.Google Scholar
Croom, KF, Perry, CM, Plosker, GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23(5): 427–452.CrossRefGoogle ScholarPubMed
Haasum, Y, Fastbom, J, Johnell, K. Use of antidepressants in Parkinson’s disease: a Swedish register-based study of over 1.5 million older people. Parkinsonism Relat Disord 2016; 27: 85–88.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 4 December 2022 via www.medicinescomplete.com.Google Scholar
Mirtazapine. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 4 December 2022 via www.medicinescomplete.com.Google Scholar
Mirtazapine. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 4 December 2022 via www.micromedexsolutions.com.Google Scholar
Summary of product characteristics – Mirtazapine 15 mg tablets. Aurobindo Pharma – Milpharm Ltd. Electronic Medicines Compendium: Mirtazapine 15 mg tablets – summary of product characteristics (SmPC) – (emc). Accessed on 4 December 2022 via www.medicines.org.uk.Google Scholar
Timmer, CJ, Sitsen, JM, Delbressine, LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38(6): 461–474.CrossRefGoogle ScholarPubMed